Clinical Trials Resource Center


February 25, 2002

Positive results were reported from a phase I trial of PT-141, Palatin Technologies' medication for male and female sexual dysfunction. The double-blind, placebo-controlled trial evaluated escalating doses of PT-141 in 88 healthy male subjects. Results indicated that both intranasally and subcutaneously administered PT-141 were well tolerated over a range of doses. Neither dosage form produced serious side effects, and a maximum tolerated dose could only be reached with subcutaneous dosing. Additionally, subjects who received PT-141 at effective dose levels had erections sufficient for sexual intercourse (as defined by RigiScan Plus System score) for a duration of more than one hour relative to placebo.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.